Corbus Pharmaceuticals Hldgs Inc (CRBP) Stock Price, Quote & News

Company Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally re...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 963 0100

Fax: 617 663 6085

Website: www.corbuspharma.com

Address:

500 River Ridge Drive, Norwood, United States

BEATOFtheMARKET Oct. 26 at 11:39 PM

Cycle Trading Signal plugged into AI 🔥 lists $CPS $CRBP $CRDU $CRI $CRWL

0 · Reply

Wirralboy Oct. 25 at 2:55 PM

$CRBP http://Investing.com - Piper Sandler raised its price target on Corbus Pharmaceuticals (NASDAQ:CRBP) to $51.00 from $35.00 on Monday, while maintaining an Overweight rating on the stock. Wedbush Raises Price Target on Corbus Pharmaceuticals Holdings to $38 From $31, Keeps Outperform Rating

0 · Reply

Mavrick3 Oct. 24 at 8:45 PM

$CRBP

0 · Reply

shlomiko Oct. 24 at 7:56 PM

$CRBP

0 · Reply

BEATOFtheMARKET Oct. 24 at 3:26 PM

$CRBP $CRCG $CRD.A $CRDU $CRI 🔥 List 10/10/25 results 🔥 Cycle Trading Signal plugged into AI 🔥

0 · Reply

Jckemp3 Oct. 23 at 3:44 PM

$CRBP on the 1y chart I see a cup and handle forming. 🤞

0 · Reply

birdmine Oct. 23 at 1:57 PM

$CRBP this week started so promisingly. Now, we are back to no momentum!!!😑😑😑

0 · Reply

shlomiko Oct. 22 at 1:46 PM

$CRBP

0 · Reply

Darsh21 Oct. 22 at 10:34 AM

$CRBP why isn’t it showing premarket prices today?

0 · Reply

Bio_Be_Dirty Oct. 22 at 1:27 AM

$CRBP pump it up

0 · Reply

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript

Oct 18, 2025, 3:00 AM EDT - 9 days ago

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Sep 16, 2025, 8:00 AM EDT - 5 weeks ago

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Jun 25, 2025, 8:00 AM EDT - 4 months ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Jun 24, 2025, 4:05 PM EDT - 4 months ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Jun 17, 2025, 3:42 PM EDT - 4 months ago

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

May 22, 2025, 8:00 AM EDT - 5 months ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 5 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX QURE

Mar 28, 2025, 8:00 AM EDT - 7 months ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Feb 14, 2025, 7:30 AM EST - 9 months ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Feb 11, 2025, 7:30 AM EST - 9 months ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Jan 28, 2025, 8:00 AM EST - 9 months ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Jan 6, 2025, 8:00 AM EST - 10 months ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 7:00 AM EST - 11 months ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

$FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer$

Dec 3, 2024, 7:00 AM EST - 11 months ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Nov 11, 2024, 4:12 AM EST - 1 year ago

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Sep 23, 2024, 2:01 PM EDT - 1 year ago

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN GPCR SRRK VKTX

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Jul 30, 2024, 8:50 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jun 3, 2024, 1:03 PM EDT - 1 year ago

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Jun 1, 2024, 10:00 AM EDT - 1 year ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

May 30, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 9, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Feb 28, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Feb 6, 2024, 9:50 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 2, 2024, 4:01 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 31, 2024, 9:19 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Jan 30, 2024, 6:55 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Jan 30, 2024, 7:13 AM EST - 1 year ago

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 29, 2024, 2:17 PM EST - 1 year ago

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Jan 29, 2024, 7:18 AM EST - 1 year ago

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

Jan 26, 2024, 7:30 AM EST - 1 year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Jan 23, 2024, 8:00 AM EST - 1 year ago

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Jan 9, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Dec 18, 2023, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

Nov 7, 2023, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

BEATOFtheMARKET Oct. 26 at 11:39 PM

Cycle Trading Signal plugged into AI 🔥 lists $CPS $CRBP $CRDU $CRI $CRWL

0 · Reply

Wirralboy Oct. 25 at 2:55 PM

0 · Reply

Mavrick3 Oct. 24 at 8:45 PM

$CRBP

0 · Reply

shlomiko Oct. 24 at 7:56 PM

$CRBP

0 · Reply

BEATOFtheMARKET Oct. 24 at 3:26 PM

$CRBP $CRCG $CRD.A $CRDU $CRI 🔥 List 10/10/25 results 🔥 Cycle Trading Signal plugged into AI 🔥

0 · Reply

Jckemp3 Oct. 23 at 3:44 PM

$CRBP on the 1y chart I see a cup and handle forming. 🤞

0 · Reply

birdmine Oct. 23 at 1:57 PM

$CRBP this week started so promisingly. Now, we are back to no momentum!!!😑😑😑

0 · Reply

shlomiko Oct. 22 at 1:46 PM

$CRBP

0 · Reply

Darsh21 Oct. 22 at 10:34 AM

$CRBP why isn’t it showing premarket prices today?

0 · Reply

Bio_Be_Dirty Oct. 22 at 1:27 AM

$CRBP pump it up

0 · Reply

Cricket23 Oct. 21 at 5:05 PM

$CRBP Definitely looks like the early morning move downwards today was to shake out all of the weak hands. Know the value of the company you hold. CRBP just reported very good results and there is more positive news on the way. We should see $30 in the next couple of trading days. This company has a very valuable pipeline of products. Holding Strong!

0 · Reply

Unterhund70 Oct. 21 at 2:20 PM

$CRBP With the volume of shares traded yesterday and the strong recovery following the morning sell-off, it is pretty clear that there are big buyers for these shares. Micro/small caps will always attract shannanigans around large positioning. I would be cautious of reading too much into these wild swings.. I could be wrong, but it just feels like a large buyer trying to shake some liquidity loose. The recent data was very good, and there is plenty of news still to come between now and year end... long and patient.

1 · Reply

BlackjackAces Oct. 21 at 1:45 PM

$CRBP trying to understand the shorting now. Desperation? Lots of volune yesterday, today hardly any but still moved it a buck already. I added.

0 · Reply

Quantumup Oct. 20 at 7:30 PM

Piper Sandler⬆️ $CRBP's PT to $51 from $35, reiterated at Overweight, and said Data Provides Proof of Efficacy for CRB-701 in HNSCC and Cervical $MRUS - $GMAB $PFE Piper Sandler added:

0 · Reply

nova_fx9 Oct. 20 at 7:06 PM

$CRBP Time of day effects shape volatility, spreads, and liquidity ⏱️. The open and close behave differently than midday, affecting slippage, stops, and exits. Aligning setups to sessions improves execution. When does your strategy perform best during the trading day?

0 · Reply

Jckemp3 Oct. 20 at 7:04 PM

$CRBP lets hope it is a strong power hour

1 · Reply

stormsideWeather Oct. 20 at 5:05 PM

$CRBP narrowing spreads signal expansion risk. Entry 2.36, stop 2.25, PT 2.68. Hourly close above 2.42 with 1.6 times 20D volume is go. Target window 2 to 6 sessions.

0 · Reply

shoagh12 Oct. 20 at 4:47 PM

$CRBP back to 100

1 · Reply

MitchOnX Oct. 20 at 3:21 PM

$CRBP $CRBP Corbus Pharmaceuticals Holdings Inc - 60 Second Analysis - October... https://youtu.be/PIDWEqi9oFY?si=KCRFF3FIWDtl9rsX via @YouTube

0 · Reply

Darsh21 Oct. 20 at 2:57 PM

$CRBP this one’s crazy!!

2 · Reply

shlomiko Oct. 20 at 2:53 PM

$CRBP dark green by the end of the day…..

0 · Reply

CalinxDaniel Oct. 20 at 2:25 PM

$CRBP Hmm..

0 · Reply

Market Cap	206.86M
Revenue (ttm)	0.00
Net Income (ttm)	-40.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	387,500
Avg Vol	229,016
Day's Range	N/A - N/A
Shares Out	12.26M
Stochastic %K	21%
Beta	2.84
Analysts	Strong Sell
Price Target	$43.22